Kylo-12 / Kylonova Biopharma - LARVOL DELTA

Kylo-12-I-C01: Single-ascending Dose Study of Kylo-12 in Healthy Subjects (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: Kylonova (Xiamen) Biopharma co., LTD. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Dyslipidemia • Hypertriglyceridemia